These genes were selected because: (1) of their overexpression in HCC patients (SCN8A in 41%, ACTN1 in 22%, SRD5A2 in 5%, NFkB2 in 56%, NEURL1B in 46%); (2) of their action as oncogenes in cancer cells (and particularly in HCC) has been less explored in previous studies (with the exception of NFkB2 and SRD5A). The gene discussed is SCN8A; the disease is hepatocellular carcinoma.